Pharmacological treatment of Parkinson’s disease
Open Access
- 1 October 2000
- journal article
- review article
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 76 (900) , 602-610
- https://doi.org/10.1136/pmj.76.900.602
Abstract
In the following sections a summary of drugs currently in use in the UK will be provided. The optimum use of antiparkinsonian drugs and the timing of treatment are matters of debate. This will be discussed later. Also, dose recommendations will be given later.Keywords
This publication has 113 references indexed in Scilit:
- Treatment of Parkinson's disease should begin with a dopamine agonistMovement Disorders, 1999
- EntacaponeDrugs, 1999
- Mortality in DATATOP: A Multicenter trial in early Parkinson's diseaseAnnals of Neurology, 1998
- Serotonin, Dopamine, and Motor Effects in Parkinsonʼs DiseaseClinical Neuropharmacology, 1997
- Ropinirole in the Treatment of Levodopa-Induced Motor Fluctuations in Patients with Parkinson's DiseaseClinical Neuropharmacology, 1996
- Comparative Review of Dopamine Receptor Agonists in Parkinsonʼs DiseaseCNS Drugs, 1996
- General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferaseGeneral Pharmacology: The Vascular System, 1994
- Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain studyEuropean Journal of Pharmacology: Molecular Pharmacology, 1991
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989
- The “On–Off” Phenomenon in Parkinson’s DiseaseNew England Journal of Medicine, 1984